Article
Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.
ESMO open - 1 Feb 2026
Planchard D, Mazières J, Grouin J M, Le Reun C, Luttenauer H, Boussahoua M, Macabeo B
Abstract excerpt
BACKGROUND: The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)V600E-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.